BYSI BeyondSpring Price Target

NASDAQ:BYSI   BeyondSpring, Inc.
BYSI BeyondSpring drug, plinabulin, increased overall survival and improved other measures of disease while staving off a dangerous side effect associated with Chemotherapy.

BeyondSpring is preparing to ask for plinabulin approval in the U.S. and China.

On 8/4/2021 J. Pantginis from HC Wainwright brokerage Upgraded BYSI BeyondSpring from Neutral to Buy giving a Price Target of $100.00

My price target is the all time high resistance of 48usd until we hear some news from the FDA.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.